The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann ...

Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a ...

Potential Pitfalls of the Rapid Uptake of New Technology in Surgery: Can Comparative Effectiveness Research Help? Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...

Sirolimus may be an effective treatment for patients with persistent cutaneous sarcoidosis. In a small clinical trial, 7 of 10 patients treated with sirolimus via oral solution had improvements in ...

University of Oxford-led research finds low-dose rapamycin functions as a genomic protector in aging human immune cells, lowering DNA damage. Subscribe to our newsletter for the latest sci-tech news ...

Naomi Haas, of the Abramson Cancer Center, explains the potential side effects of a class of drugs called mTOR inhibitors, primarily the agents Sutent and Nexavar. Naomi Haas, of the Abramson Cancer ...

The liver plays a central role in maintaining systemic energy homeostasis during fasting by mobilizing lipid reserves, a process often accompanied by transient hepatic steatosis. Dimethylarginine ...

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy and other brain disorders. The $550 million-plus deal ...